



2021 MCAS MEASURE: CHLAMYDIA SCREENING IN WOMEN AGES 16-24 (CHL)

Measure Steward: National Committee for Quality Assurance (NCQA)

Gold Coast Health Plan's (GCHP) goal is to help its providers gain compliance with their annual Managed Care Accountability Set (MCAS) scores by providing guidance and resources. This tip sheet will provide the key components to the MCAS measure, "*Chlamydia Screening in Women Ages 16-24 (CHL)*."

Measure Description: *The percentage of women ages 16-24 who were identified as sexually active and who had at least one test for chlamydia during the measurement year.*

Data Collection Method: Administrative¹

Criteria to identify Eligible Population

- ▶ Evidence of sexual activity. Click [here](#) for a complete list of codes (ICD-10-CM, CPT, HCPCPS and SNOMED).
AND/OR
- ▶ Evidence of contraceptive prescription dispensing.

Contraceptive Medications

Description	Prescription
Contraceptives	Desogestrel-ethinyl estradiol Dienogest-estradiol multiphasic Drospirenon-ethinyl estradiol Drospirenone-ethinyl estradiol-levomefolate biphasic Ethinyl estradiol-ethynodiol Ethinyl estradiol-etonogestrel Ethinyl estradiol-folic acid-levonorgestrel Ethinyl estradiol-levonorgestrel Ethinyl estradiol-norelgestromin Ethinyl estradiol-norethindrone Ethinyl estradiol-norgestimate Ethinyl estradiol-norgestrel Etonogestrel Levonorgestrel Medroxyprogesterone Mestranol-norethinndrone Norethindrone
Diaphragm	Diaphragm
Spermicide	Nonxynol 9



CHL Clinical Code Sets

- ▶ For billing, reimbursement, and reporting of services completed, submit claims timely with the appropriate medical codes for all clinical conditions evaluated and services completed.

Codes used to identify chlamydia screening in women.

Description	CPT	LOINC	SNOMED
Chlamydia Test	87110, 87270, 87320, 87490, 87491, 87492, 87810	14463-4, 14464-2, 14467-5, 14474-1, 14513-6, 16600-9, 21190-4, 21191-2, 21613-5, 23838-6, 31775-0, 31777-6, 36902-5, 36903-3, 42931-6, 43304-5, 43404-3, 43405-0, 43406-8, 44806-8, 44807-6, 45068-4, 45069-2, 45075-9, 45076-7, 45084-1, 45091-6, 45095-7, 45098-1, 45100-5, 47211-8, 47212-6, 49096-1, 4993-2, 50387-0, 53925-4, 53926-2, 557-9, 560-3, 6349-5, 6354- 5, 6355-2, 6356-0, 6357-8, 80360-1, 80361-9, 80362-7, 91860-7	104175002, 104281002, 104282009, 104290009, 117775008, 121956002, 121957006, 121958001, 121959009, 122173003, 122254005, 122321005, 122322003, 134256004, 134289004, 171120003, 285586000, 310861008, 310862001, 315087006, 315094009, 315095005, 315099004, 390784004, 390785003, 395195000, 398452009, 399193003, 407707008, 442487003, 707982002

Exclusion Criteria – Members with any of the following conditions are excluded from the CHL measure:

- ▶ Members who received hospice care during the measurement year.
- ▶ Members who had a pregnancy test during the measurement year and one of the following:
 - Received a prescription of isotretinoin on the date of the pregnancy test or within the six days after the test.
 - Received a diagnostic radiology exam on the date of the pregnancy test or within the six days after the test.

Best Practices:

- ▶ Use the Inovalon® INDICES® Provider Insights Dashboards to identify members with gaps in care.
- ▶ Provide training to all medical staff to empower them to educate and encourage screening during interactions with appropriate population. Include training and implementation of appropriate Sexual History Screening tool with a focus on the younger population. Building trust throughout the process is a key element to ensure compliance.
- ▶ Collect a sample when patient voids prior to pelvic exam and have a discussion in a private setting regarding CHL screening. An additional strategy is to place a UA sample cup or CHL swab on the tray when setting up the exam room for all visits with a women's health provider. This can help prompt a discussion regarding CHL screening and increase the ease of sample collection.
- ▶ Include chlamydia screening as a part of routine clinical preventive care.
- ▶ Use normalizing and opt-out language, such as, "I recommend a test for chlamydia to all my clients under the age of 25." AVOID questions like, "Do you want to be tested for chlamydia today?"
- ▶ Use the least invasive and highest quality recommended laboratory technologies available.
- ▶ Cultural competency is not just limited to race, ethnicity and culture. Perceptions, values, beliefs and trust can also be influenced by factors such as religion, age, sexual orientation, gender identity and socioeconomic status.
- ▶ Ensure screening is ordered when it is due, regardless of the reason for the visit.
- ▶ For patients who completed a prior women's health visit at a different clinic, specifically request any prior CHL screenings. Upon receipt, assess and document the date, location, and result of their last screening and have the physician sign the note. Also, have the patient sign a release of records.

¹ Measures reported using the *administrative* data collection method report on the entire eligible population and use only administrative data sources (e.g. claims, encounter, lab, immunization registries) to evaluate if services were performed.